CN106132969A - 用于治疗糖尿病和肝病的组合物和方法 - Google Patents

用于治疗糖尿病和肝病的组合物和方法 Download PDF

Info

Publication number
CN106132969A
CN106132969A CN201580015346.1A CN201580015346A CN106132969A CN 106132969 A CN106132969 A CN 106132969A CN 201580015346 A CN201580015346 A CN 201580015346A CN 106132969 A CN106132969 A CN 106132969A
Authority
CN
China
Prior art keywords
group
unit dosage
solithromycin
optionally substituted
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580015346.1A
Other languages
English (en)
Chinese (zh)
Inventor
P·费尔南德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of CN106132969A publication Critical patent/CN106132969A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201580015346.1A 2014-02-14 2015-02-11 用于治疗糖尿病和肝病的组合物和方法 Pending CN106132969A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461939961P 2014-02-14 2014-02-14
US61/939,961 2014-02-14
US201461984225P 2014-04-25 2014-04-25
US61/984,225 2014-04-25
US201462086911P 2014-12-03 2014-12-03
US62/086,911 2014-12-03
PCT/US2015/015353 WO2015123256A1 (en) 2014-02-14 2015-02-11 Compositions and methods for treating diabetes and liver diseases

Publications (1)

Publication Number Publication Date
CN106132969A true CN106132969A (zh) 2016-11-16

Family

ID=53800574

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580015346.1A Pending CN106132969A (zh) 2014-02-14 2015-02-11 用于治疗糖尿病和肝病的组合物和方法

Country Status (12)

Country Link
US (1) US20170165286A1 (https=)
EP (1) EP3105234A4 (https=)
JP (2) JP6553067B2 (https=)
KR (1) KR20160113307A (https=)
CN (1) CN106132969A (https=)
AU (1) AU2015217293A1 (https=)
CA (1) CA2939076A1 (https=)
IL (1) IL247152A0 (https=)
MX (1) MX2016010447A (https=)
RU (1) RU2016133471A (https=)
WO (1) WO2015123256A1 (https=)
ZA (1) ZA201606199B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110198719A (zh) * 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
AU2009308182B2 (en) 2008-10-24 2016-05-19 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
LT4406594T (lt) 2012-09-17 2025-12-29 Madrigal Pharmaceuticals, Inc. Skydliaukės hormono analogai
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
IL266054B2 (en) * 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
JP2024044227A (ja) * 2022-09-20 2024-04-02 国立大学法人岩手大学 グルコース産生抑制剤
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760010A (en) * 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
CN101454334A (zh) * 2006-05-01 2009-06-10 大正制药株式会社 大环内酯衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2292359C (en) * 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2897154B1 (fr) * 2006-02-08 2008-03-07 Airbus France Sas Dispositif pour construire et securiser une trajectoire de vol a basse altitude destinee a etre suivie par un aeronef.
JP5025249B2 (ja) * 2006-12-15 2012-09-12 Ｎｓｋワーナー株式会社 発進クラッチ
JP5150740B2 (ja) * 2011-01-21 2013-02-27 株式会社小松製作所 作業車両
CA2845108C (en) * 2011-08-30 2015-06-16 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
US9078975B2 (en) * 2011-09-30 2015-07-14 Becton Dickinson France, S.A.S. Syringe having pivoting arm plunger rod

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760010A (en) * 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
CN101454334A (zh) * 2006-05-01 2009-06-10 大正制药株式会社 大环内酯衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110198719A (zh) * 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法

Also Published As

Publication number Publication date
IL247152A0 (en) 2016-09-29
MX2016010447A (es) 2016-12-20
KR20160113307A (ko) 2016-09-28
EP3105234A1 (en) 2016-12-21
AU2015217293A1 (en) 2016-09-01
ZA201606199B (en) 2020-01-29
US20170165286A1 (en) 2017-06-15
WO2015123256A1 (en) 2015-08-20
JP6553067B2 (ja) 2019-07-31
CA2939076A1 (en) 2015-08-20
EP3105234A4 (en) 2017-11-08
RU2016133471A3 (https=) 2018-09-24
JP2017505785A (ja) 2017-02-23
RU2016133471A (ru) 2018-03-19
JP2019189639A (ja) 2019-10-31

Similar Documents

Publication Publication Date Title
JP6553067B2 (ja) 糖尿病および肝疾患を治療するための組成物および方法
US11419878B2 (en) Medicine obtained by combining FXR agonist and ARB
US10117855B2 (en) Methods of treatment for cholestatic and fibrotic diseases
EP3223829B1 (en) Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
KR102034703B1 (ko) 비알코올성 지방성 간 질환 치료제
CN111479574B (zh) 用于治疗和预防细胞外组蛋白介导的病理的化合物
TW201818935A (zh) 治療肝臟疾病之方法
US20180338992A1 (en) Il-34 antisense oligonucleotides and methods of using same
KR20130113921A (ko) 비알코올성 지방성 간염의 예방 및/또는 치료제
WO2020006199A2 (en) Methods and agents for modulating inflammation
HK1231075A1 (en) Compositions and methods for treating diabetes and liver diseases
CN117980001A (zh) 用于预防或治疗炎症性肠病的包含肠类器官和抗炎剂的药物组合物
US20160120938A1 (en) P2x7 receptor agonist for use in preventing or treating kidney injury
US20070072937A1 (en) Pharmaceutical composition comprising alpha-lipoic acid for inflammatory diseases
JP2022527762A (ja) オベチコール酸を用いた肝疾患の診断および処置の方法
JP2022514672A (ja) ヒアルロナン合成阻害のための４－メチルウンベリフェリルグルクロニド
CN118453879A (zh) 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用
JP2012102029A (ja) アセトアミノフェン肝傷害治療剤
HK1260722A1 (en) Medicine obtained by combining fxr agonist and arb

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231075

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161116

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1231075

Country of ref document: HK